Nucleon Swot Analysis

537 Words3 Pages
SWOT ANALYSIS A scan of the internal and external environment is an important part of the strategic planning process. Environmental factors internal to the firm usually can be classified as strengths (S) or weaknesses (W), and those external to the firm can be classified as opportunities (O) or threats (T). This is referred to as a SWOT analysis. The SWOT analysis provides information that is helpful in matching the firm’s resources and capabilities to the competitive environment in which it operates. INTERNAL ANALYSIS Strengths A firm’s strengths are its resources and capabilities that can be used as a basis for developing a competitive advantage. Such strengths can be gained from tangible or intangible resources, or a combination of both. Nucleon’s strengths include: * Tight links with the academic/research community – if someone was able to clone the genes for a new cell regulating factor, Nucleon management would know about this immediately giving them an advantage over its competitors. * Strong patent position on the CRP-1 molecule – Nucleon has exclusive rights to the molecule that the company develops. * Promising pre-clinical trials of the CRP-1 molecule – Nucleon is able to test their drugs on animals. If successful at the stage then they move to testing on humans who volunteer before distributing it worldwide. Weaknesses Some weaknesses identified with Nucleon are: * Small size private held company – Nucleon cannot have a big portfolio of project like the larger companies. Due to this disadvantage the company has to select a winner project the first time around. * Weak patent position on the genetic sequence * Capital availability – potential corporate partners who had been disappointed by previous biotechnology relationship were unwilling to fund early stage projects. * R&D resources focused on the
Open Document